Post Offer Free
Bolise Co., Ltd.  

Gold Index: 5848

You are here: home  > Plant Extract  > What is Paclitaxel ?

What is Paclitaxel ? 

Payment Terms: WU,Paypal 
Place of Origin: Guangxi, China (Mainland) 
inquire
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: Paclitaxel-
plant extracts: herbal extracts
Means of Transport: Ocean,Land,Air

Paclitaxel is a natural product with antitumor activity. Paclitaxel is obtained via a semi-synthetic process from Taxus baccata.

Product name: Paclitaxel

CAS Number:  33069-62-4

Molecular Formula:  C47H51NO14

Molecular Weight:  853.90.

storage condition desiccated:protect from light 

storage temp: 0~4°C

Packing: Preserved in tight container 500g /bottle or in demand 

Descriptions:

Paclitaxel is a natural product with antitumor activity. Paclitaxel is obtained via a semi-synthetic process from Taxus baccata. The chemical name for Paclitaxel is 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13- ester with (2R,3S)-N-benzoyl-3-phenylisoserine.

Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. Paclitaxel is now used to treat patients with lung, ovarian, breast cancer, head and neck cancer, and advanced forms of Kaposi's sarcoma. Paclitaxel is also used for the prevention of restenosis.

Paclitaxel should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available.

Anaphylaxis and severe hypersensitivity reactions characterized by dyspnea and hypotension requiring treatment, angioedema, and generalized urticaria have occurred in 2 to 4% of patients receiving Paclitaxel in clinical trials. Fatal reactions have occurred in patients despite premedication. All patients should be pretreated with corticosteroids, diphenhydramine, and H2 antagonists (see DOSAGE AND ADMINISTRATION). Patients who experience severe hypersensitivity reactions to Paclitaxel should not be rechallenged with the drug.

Paclitaxtel therapy should not be given to patients with solid tumors who have baseline neutrophil counts of less than 1,500 ccells/mm3 and should not be given to patients with AIDS-related Kaposi's sarcoma if the baseline neutrophil count is less than 11,000 cells/mm3. In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving Paclitaxel.


bigPhoto
 Mr. sale

Tel: 86-592-5365868
Contact to this supplier

Related Search

Find more related products in following catalogs on Hisupplier.com

Company Info

Bolise Co., Ltd. [China (Mainland)]


Business Type:Manufacturer, Trading Company
City: Xiamen
Province/State: Fujian
Country/Region: China (Mainland)

You May Like:

Product (110)